Navigation Links
Clinical Update - Debio 025 Cyclophilin Inhibitor for the Treatment,of HCV

A Unique Viral Kinetics Profile

LAUSANNE, Switzerland, April 19, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist in oncology and serious medical conditions, presented additional results of a previous phase Ib, 15 day study with cyclophilin (Cyp) inhibitor Debio 025 in HIV/HCV (hepatitis C virus) co-infected patients. The data were presented at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain. Mathematical modelling of the viral decay shows that Debio 025 has a unique viral kinetics profile without signs of emerging resistance during short term treatment.

Other data from the same study showed that during treatment, Cyp-B levels decreased significantly in peripheral blood mononuclear cells (PBMCs) after treatment with Debio 025. The drop in Cyp-B levels paralleled the 3.6 log10 decrease reported earlier in this study. These human data confirm previous in vitro results that have shown that Cyp-B inhibition leads to the depletion of intracellular Cyp-B levels in the HCV replicon, as well as in other cell culture models. These are the first preliminary human data that support the hypothesis that intracellular CypB depletion is associated with significant anti-HCV activity and that CypB inhibition is a valid new target for the development of anti-HCV drugs.

"We are very excited about these results. To date, we have finalised the first two cohorts of our phase IIa study in treatment-naive mono-infected HCV patients, where we examined the effect of increasing doses of Debio 025 in combination with pegylated interferon. The Data Management Committee has analysed all safety and efficacy data and authorised the initiation of the cohort with the highest dose in the protocol," said Kamel Besseghir, CEO of Debiopharm S.A.

About Debio 025

Debio 025 is a synthetic first-in-class
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical Update Debio Cyclophilin Inhibitor for the Treatment HCV
(Date:3/26/2015)... A new survey of health care ... (CER) will yield improvements in health care decision-making, ... of CER in the current environment. The National ... shows that they view CER as important, expect ... and decision-making in the next three to five ...
(Date:3/26/2015)... 2015 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... to serve as a feature-rich resource for patients of its ... For those experiencing knee pain, the Gel-One Patient ... knee pain and helps them understand more about the potential ... non-surgical treatment option. For those who have had a ...
(Date:3/26/2015)... ROCKVILLE, Md. , March 26, 2015  RegeneRx ... that it has received a patent acceptance notice from ... beta 4 (TB4) to prevent or reduce tissue damage ... often the case when cardiac vessels are opened after ... circumstances when treating stroke victims. Damage can ...
Breaking Medicine Technology:NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making 2NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making 3NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making 4Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3
... 16 BioVex Inc, a biotechnology,company developing clinical ... that the abstract describing the interim results,from its ... advanced metastatic,melanoma is now available at the American ... http://www.asco.org . A summary of the abstract,which describes ...
... Nektar,s Technology Enables First-Ever PEGylation of a Small Molecule with ... Demonstrated Therapeutic ... NKTR ) announced initial results today from a Phase ... activity in patients with refractory solid tumors. The study,also demonstrates ...
Cached Medicine Technology:BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5
(Date:3/26/2015)... Visiting Nurse Association of Northern New Jersey ... the Way, Brightening the Day, on Friday, May 1, ... Morristown, NJ. , Guests will enjoy an elegant ... delightful cuisine, an extensive silent auction and heart-warming testimony ... awards will be presented to this year’s honorees. ...
(Date:3/26/2015)... San Juan Capistrano, Calif. (PRWEB) March 26, 2015 ... monitoring equipment and repairs, is pleased to be featured ... the Discovery Channel on March 18, 2015. The ... status, and it is live on the Pacific Medical ... families that face life threatening emergencies, it is reassuring ...
(Date:3/26/2015)... Silver Spring, Md. (PRWEB) March 26, 2015 ... (PHA) fully supports the Patients’ Access to Treatments ... of Representatives this week by Reps. David B. ... bi-partisan legislation will limit cost-sharing requirements for medications ... medications more accessible by reducing patients’ out-of-pocket expenses. ...
(Date:3/26/2015)... FL (PRWEB) March 26, 2015 ... its brand-new, state-of-the-art company website: http://www.metabolicnutrition.com . ... the revamped website creates a user-friendly experience for ... company. , The new, enhanced Metabolic Nutrition ... information about the company’s diverse line of products, ...
(Date:3/26/2015)... Chicago, Ill. (PRWEB) March 26, 2015 ... celebrate the legacy of a man who revolutionized the ... (BCL) posthumously honored Leo Passage; founder of Pivot Point ... the award on behalf of Leo. Held at the ... by a “who’s who” of industry and media leaders ...
Breaking Medicine News(10 mins):Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2Health News:Metabolic Nutrition Launches Sleek New Website with New Features and Enhanced Consumer Information 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 2Health News:#BeautyChangesLives Legacy Award Pays Tribute to Industry Icon Leo Passage 3
... custom chopper!, PITTSBURGH, May 7 GNC ... Sonia Adcock at the Contra Costa Bodybuilding,Fitness and ... Performing,Arts Center in Hayward, Calif., Garcia and ... Federation,of Bodybuilding (IFBB) fitness and figure competitors. The ...
... DALLAS, May 7 The American Heart ... its second of the,planned six-publication extension to the ... Association. The journals will,be published by Lippincott Williams ... James E. Udelson, M.D., acting chief of the ...
... who speak a second or third language may have ... Aviv University study has found. Knowing and speaking many ... aging. , Dr. Gitit Kav, a clinical neuro-psychologist from ... together with her colleagues Nitza Eyal, Aviva Shorek, and ...
... Health, a global,provider of products and services that improve ... board of directors has approved a 17,percent increase in ... The regular quarterly dividend is payable on July 15 ... paid a 12-cents-per-share quarterly,dividend since July 15, 2007 and ...
... This release is available in Spanish ... Diabetes Federation (IDF) BRIDGES translational research grant program ... that will offer culturally appropriate and improved diabetes ... , The community-based study, Diabetes Self-Management Program (DSME), ...
... Patients, nurses,physicians and other hospital and healthcare advocates ... May 12 to protest the nearly $300,million in healthcare ... WHAT: "Care Today, Gone Tomorrow," a Rally to Preserve ... Street, Trenton, WHEN: 12 noon, May 12, ...
Cached Medicine News:Health News:Fitness and Figure Professionals Adela Garcia and Sonia Adcock to Represent GNC at Contra Costa Championship 2Health News:American Heart Association Announces Next New Journal - Circulation: Heart Failure Set for May Premier 2Health News:American Heart Association Announces Next New Journal - Circulation: Heart Failure Set for May Premier 3Health News:Tel Aviv University finds connection between mental fitness and multi-lingualism 2Health News:Cardinal Health Increases Quarterly Dividend by 17 Percent 2Health News:International Diabetes Federation gives grant to Philippine diabetes education program 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: